| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Cover [Abstract] | |
| Document Type | DEF 14A |
| Amendment Flag | false |
| Entity Registrant Name | Arcus Biosciences, Inc. |
| Entity Central Index Key | 0001724521 |
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Pay vs Performance Disclosure [Table] | |||
| Pay vs Performance [Table Text Block] | Pay versus Performance The following table discloses additional compensation information of our CEO and other NEOs (Other NEOs), including “compensation actually paid” during the specified years alongside total shareholder return (TSR) and net income metrics: Value of initial fixed $100 investment based on: Summary compensation table total for CEO Compensation actually paid to CEO (2)(3) Average summary compensation table total for Other NEOs Average Compensation actually paid to Other NEOs (2)(4) Total shareholder return (5) Peer group total shareholder return (5) Net income (6) Year (1) ($) ($) ($) ($) ($) ($) ($ millions) 2022 9,048,432 ( 2,065,105 ) 4,191,618 ( 2,394,074 ) 204.75 87.61 ( 267 ) 2021 9,483,339 14,577,932 5,939,512 7,091,681 400.69 117.83 53 2020 5,685,664 12,015,409 5,363,707 10,455,559 257.03 148.03 ( 123 ) (1) Our CEO for each of the years presented was Dr. Rosen . Our Other NEOs for 2022 were Bob Goeltz, Juan Jaen, Jennifer Jarret and Dimitry Nuyten . Our Other NEOs for 2021 were Bob Goeltz, Juan Jaen, Jennifer Jarret, Carolyn Tang and William Grossman . Our Other NEOs for 2020 were Jennifer Jarrett and William Grossman . (2) Fair value or change in fair value, as applicable, of equity awards in the "compensation actually paid" columns was determined by reference to (i) for RSU awards, closing price on applicable year-end dates or, in the case of vesting dates, the actual vesting price and (ii) for stock options, the fair value estimated using a binomial lattice model as of the applicable year-end or vesting date(s). Key inputs included the contractual terms of each agreement such as vesting date, maturity date, and exercise price, while additional key inputs included the closing stock price, volatility, dividend rates, risk free rates, and an early-exercise factor which were all determined as of the revaluation date. (3) The adjustments made to the summary compensation table total for Dr. Rosen's for each year presented above to determine compensation actually paid to Dr. Rosen in such year are shown in the tables below: 2022 2021 2020 Summary compensation table total 9,048,432 9,483,339 5,685,664 Less, value of stock & option awards ( 8,292,320 ) ( 8,548,858 ) ( 5,356,475 ) Plus year-end value of awards granted in fiscal year that are unvested and outstanding 3,788,462 7,142,260 7,893,097 Plus change in fair value of prior year awards that are outstanding and unvested ( 5,490,389 ) 3,923,736 1,828,423 Plus FMV as of the vesting date of awards granted this year and that vested this year 1,608,814 1,783,385 1,108,163 Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year ( 2,728,104 ) 794,070 856,538 Total adjustments ( 11,113,537 ) 5,094,593 6,329,745 Compensation actually paid ( 2,065,105 ) 14,577,932 12,015,409 (4) The adjustments made to the average summary compensation table total for Other NEOs for each year presented above to determine average compensation actually paid to Other-NEOs in such year are shown in the tables below: 2022 2021 2020 Summary compensation table total 4,191,618 5,939,512 5,363,707 Less, value of stock & option awards ( 3,444,851 ) ( 5,298,516 ) ( 4,864,788 ) Plus year-end value of awards granted in fiscal year that are unvested and outstanding 1,848,729 3,797,282 6,969,591 Plus change in fair value of prior year awards that are outstanding and unvested ( 4,050,986 ) 2,678,504 1,656,950 Plus FMV as of the vesting date of awards granted this year and that vested this year 528,662 1,094,353 509,856 Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year ( 1,467,247 ) 678,367 820,243 Less, prior year fair value of prior year awards that failed to vest this year - ( 1,827,217 ) - Plus adjustments for stock modification - 29,396 - Total adjustments ( 6,585,693 ) 1,152,169 5,091,852 Compensation actually paid ( 2,394,074 ) 7,091,681 10,455,559 (5) TSR figures assume an initial investment in our common stock of $100 on December 31, 2019. The peer group referenced for purpose of the TSR comparison is the group of companies included in the S&P Biotechnology Index, which is the industry peer group used for purposes of Item 201(e) of Regulation S-K. The separate peer group used by the Compensation Committee for purposes of determining compensation paid to our executive officers is described on page 27 . (6) Reflects after-tax net income attributable to stockholders prepared in accordance with GAAP for each of the years shown. | ||
| Named Executive Officers, Footnote [Text Block] | Our CEO for each of the years presented was Dr. Rosen . Our Other NEOs for 2022 were Bob Goeltz, Juan Jaen, Jennifer Jarret and Dimitry Nuyten . Our Other NEOs for 2021 were Bob Goeltz, Juan Jaen, Jennifer Jarret, Carolyn Tang and William Grossman . Our Other NEOs for 2020 were Jennifer Jarrett and William Grossman . | ||
| Peer Group Issuers, Footnote [Text Block] | The peer group referenced for purpose of the TSR comparison is the group of companies included in the S&P Biotechnology Index, which is the industry peer group used for purposes of Item 201(e) of Regulation S-K. The separate peer group used by the Compensation Committee for purposes of determining compensation paid to our executive officers is described on page 27 . | ||
| PEO Total Compensation Amount | $ 9,048,432 | $ 9,483,339 | $ 5,685,664 |
| PEO Actually Paid Compensation Amount | $ (2,065,105) | 14,577,932 | 12,015,409 |
| Adjustment To PEO Compensation, Footnote [Text Block] | Fair value or change in fair value, as applicable, of equity awards in the "compensation actually paid" columns was determined by reference to (i) for RSU awards, closing price on applicable year-end dates or, in the case of vesting dates, the actual vesting price and (ii) for stock options, the fair value estimated using a binomial lattice model as of the applicable year-end or vesting date(s). Key inputs included the contractual terms of each agreement such as vesting date, maturity date, and exercise price, while additional key inputs included the closing stock price, volatility, dividend rates, risk free rates, and an early-exercise factor which were all determined as of the revaluation date. The adjustments made to the summary compensation table total for Dr. Rosen's for each year presented above to determine compensation actually paid to Dr. Rosen in such year are shown in the tables below: 2022 2021 2020 Summary compensation table total 9,048,432 9,483,339 5,685,664 Less, value of stock & option awards ( 8,292,320 ) ( 8,548,858 ) ( 5,356,475 ) Plus year-end value of awards granted in fiscal year that are unvested and outstanding 3,788,462 7,142,260 7,893,097 Plus change in fair value of prior year awards that are outstanding and unvested ( 5,490,389 ) 3,923,736 1,828,423 Plus FMV as of the vesting date of awards granted this year and that vested this year 1,608,814 1,783,385 1,108,163 Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year ( 2,728,104 ) 794,070 856,538 Total adjustments ( 11,113,537 ) 5,094,593 6,329,745 Compensation actually paid ( 2,065,105 ) 14,577,932 12,015,409 | ||
| Non-PEO NEO Average Total Compensation Amount | $ 4,191,618 | 5,939,512 | 5,363,707 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ (2,394,074) | 7,091,681 | 10,455,559 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | The adjustments made to the average summary compensation table total for Other NEOs for each year presented above to determine average compensation actually paid to Other-NEOs in such year are shown in the tables below: 2022 2021 2020 Summary compensation table total 4,191,618 5,939,512 5,363,707 Less, value of stock & option awards ( 3,444,851 ) ( 5,298,516 ) ( 4,864,788 ) Plus year-end value of awards granted in fiscal year that are unvested and outstanding 1,848,729 3,797,282 6,969,591 Plus change in fair value of prior year awards that are outstanding and unvested ( 4,050,986 ) 2,678,504 1,656,950 Plus FMV as of the vesting date of awards granted this year and that vested this year 528,662 1,094,353 509,856 Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year ( 1,467,247 ) 678,367 820,243 Less, prior year fair value of prior year awards that failed to vest this year - ( 1,827,217 ) - Plus adjustments for stock modification - 29,396 - Total adjustments ( 6,585,693 ) 1,152,169 5,091,852 Compensation actually paid ( 2,394,074 ) 7,091,681 10,455,559 | ||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | The graphs below show the relationship between (i) the compensation actually paid to both our CEO and Other NEOs for the years set forth in the Pay versus Performance Table and (ii) the net income/loss and total shareholder return for the corresponding years: | ||
| Compensation Actually Paid vs. Net Income [Text Block] | The graphs below show the relationship between (i) the compensation actually paid to both our CEO and Other NEOs for the years set forth in the Pay versus Performance Table and (ii) the net income/loss and total shareholder return for the corresponding years: | ||
| Total Shareholder Return Vs Peer Group [Text Block] | TSR figures assume an initial investment in our common stock of $100 on December 31, 2019. | ||
| Total Shareholder Return Amount | $ 204.75 | 400.69 | 257.03 |
| Peer Group Total Shareholder Return Amount | 87.61 | 117.83 | 148.03 |
| Net Income (Loss) | $ (267,000,000) | $ 53,000,000 | $ (123,000,000) |
| PEO Name | Dr. Rosen | Dr. Rosen | Dr. Rosen |
| Additional 402(v) Disclosure [Text Block] | As described above under “Compensation Discussion and Analysis,” our executive compensation program is built around a pay-for-performance framework. While we utilize various performance measures to align executive compensation with company performance, these measures are focused on the clinical development of our investigational products and, as such, are non-financial in nature. Moreover, we generally seek to incentivize long-term performance, and therefore do not specifically align the company’s performance measures with compensation that is actually paid (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. As a result, we do not have a financial performance measure as described in Item 402(v)(2)(vi) of Regulation S-K to link compensation actually paid to our performance. | ||
| Non PEO Name | Bob Goeltz, Juan Jaen, Jennifer Jarret and Dimitry Nuyten | Bob Goeltz, Juan Jaen, Jennifer Jarret, Carolyn Tang and William Grossman | Jennifer Jarrett and William Grossman |
| PEO [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (11,113,537) | $ 5,094,593 | $ 6,329,745 |
| PEO [Member] | Less, Value of Stock & Options Awards | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (8,292,320) | (8,548,858) | (5,356,475) |
| PEO [Member] | Plus Year-end Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 3,788,462 | 7,142,260 | 7,893,097 |
| PEO [Member] | Plus Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (5,490,389) | 3,923,736 | 1,828,423 |
| PEO [Member] | Plus FMV As Of The Vesting Date Of Awards Granted This Year And That Vested This Year | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,608,814 | 1,783,385 | 1,108,163 |
| PEO [Member] | Plus Change As Of The Vesting Date In Fair Value (From Prior Year-end) Of Prior Year Awards That Vested This Year | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (2,728,104) | 794,070 | 856,538 |
| Non-PEO NEO [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (6,585,693) | 1,152,169 | 5,091,852 |
| Non-PEO NEO [Member] | Less, Value of Stock & Options Awards | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (3,444,851) | (5,298,516) | (4,864,788) |
| Non-PEO NEO [Member] | Plus Year-end Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,848,729 | 3,797,282 | 6,969,591 |
| Non-PEO NEO [Member] | Plus Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (4,050,986) | 2,678,504 | 1,656,950 |
| Non-PEO NEO [Member] | Plus FMV As Of The Vesting Date Of Awards Granted This Year And That Vested This Year | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 528,662 | 1,094,353 | 509,856 |
| Non-PEO NEO [Member] | Plus Change As Of The Vesting Date In Fair Value (From Prior Year-end) Of Prior Year Awards That Vested This Year | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (1,467,247) | 678,367 | $ 820,243 |
| Non-PEO NEO [Member] | Less, Prior Year Fair Value of Prior Year Awards That Failed to Vest This Year | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (1,827,217) | ||
| Non-PEO NEO [Member] | Plus Adjustments for Stock Modification | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ 29,396 | ||
